Merck & Co. Inc. (MRK)

82.61
NYSE : Health Technology
Prev Close 82.76
Day Low/High 82.12 / 83.57
52 Wk Low/High 66.10 / 87.35
Avg Volume 9.73M
Exchange NYSE
Shares Outstanding 2.56B
Market Cap 213.30B
EPS 2.30
P/E Ratio 39.37
Div & Yield 2.20 (2.57%)
AstraZeneca Slides on $6.9 Billion Cancer Drug Deal with Japan's Daiichi Sankyo

AstraZeneca Slides on $6.9 Billion Cancer Drug Deal with Japan's Daiichi Sankyo

AstraZeneca shares traded near the bottom of the London market Friday after the drugmaker agreed a potential $6.9 billion deal with Japan's Daiichi Sankyo Co. to develop and market a breast and gastric cancer treatment over the coming years.

S&P 500 Returned a Record $1.26 Trillion in 2018 as Buybacks Topped $806 Billion

S&P 500 Returned a Record $1.26 Trillion in 2018 as Buybacks Topped $806 Billion

U.S.-listed stocks returned more than $1.2 trillion to investors last year, according to data published Monday by S&P Dow Jones Indices, with companies buying back a record $806.4 billion in shares thanks in part to a corporate tax windfall and a sharp market pullback in the final three months of the year.

S&P 500 Q4 2018 Buybacks Set 4th Consecutive Quarterly Record At $223 Billion; 2018 Sets Record $806 Billion

S&P 500 Q4 2018 Buybacks Set 4th Consecutive Quarterly Record At $223 Billion; 2018 Sets Record $806 Billion

- Q4 share repurchases increased 62.8% year-over-year to a record $223.0 billion

Don't Be a Hero: Cramer's 'Mad Money' Recap (Friday 3/22/19)

Don't Be a Hero: Cramer's 'Mad Money' Recap (Friday 3/22/19)

Jim Cramer says there's so much money being run by computers, stocks are virtually destined to come down in this situation. Here's the game plan.

Axon Enterprise, Perrigo, Merck: 'Mad Money' Lightning Round

Axon Enterprise, Perrigo, Merck: 'Mad Money' Lightning Round

Jim Cramer weighs in on Axon Enterprise, Perrigo, Merck, Alteryx, Enterprise Products Partners and more.

Industry Consortium Launched To Qualify Biomarkers For Schizophrenia Drug Development

Industry Consortium Launched To Qualify Biomarkers For Schizophrenia Drug Development

The ERP Biomarker Qualification Consortium was launched today by pharmaceutical industry members with the goal of qualifying event-related potential (ERP) biomarkers to aid the development of new investigational therapies for people with schizophrenia in...

Merck And NGM Bio Announce Extension Of Broad, Multi-Year Strategic Collaboration To 2022

Merck And NGM Bio Announce Extension Of Broad, Multi-Year Strategic Collaboration To 2022

Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NGM Biopharmaceuticals, Inc.

Digging Down on the Dow 30

Digging Down on the Dow 30

Just 13 of the 30 Dow components are in clear uptrends.

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) In Combination With Chemotherapy For First-Line Treatment Of Adults With Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) In Combination With Chemotherapy For First-Line Treatment Of Adults With Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA, the company's anti-PD-1 therapy, in combination with carboplatin and either paclitaxel or nab-paclitaxel, for the...

Merck Becomes #3 Most Shorted Dow Stock, Replacing MMM

Merck Becomes #3 Most Shorted Dow Stock, Replacing MMM

The most recent short interest data has been released for the 02/28/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Jim Cramer: Now We've Got FOBS, Fear of Big Sellers

Jim Cramer: Now We've Got FOBS, Fear of Big Sellers

Why are big institutions running and can you outrace them?

Merck Prices $5.0 Billion Debt Offering

Merck Prices $5.0 Billion Debt Offering

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today priced a $5.

Merck Begins Tender Offer To Acquire Immune Design

Merck Begins Tender Offer To Acquire Immune Design

Merck (NYSE: MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Immune Design (NASDAQ: IMDZ).

European Medicines Agency Adopts Positive Opinion For Merck's KEYTRUDA® (pembrolizumab) For Six-Week Dosing Schedule Across All Current Monotherapy Indications

European Medicines Agency Adopts Positive Opinion For Merck's KEYTRUDA® (pembrolizumab) For Six-Week Dosing Schedule Across All Current Monotherapy Indications

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a new extended dosing schedule for...

LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion For Use In Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer

LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion For Use In Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending the use of...

Merck Becomes #4 Most Shorted Dow Stock, Replacing Visa

Merck Becomes #4 Most Shorted Dow Stock, Replacing Visa

The most recent short interest data has been released for the 02/15/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

LYNPARZA® (olaparib) Reduced The Risk Of Disease Progression Or Death As First-Line Maintenance Treatment In Germline BRCA-Mutated Metastatic Pancreatic Cancer

LYNPARZA® (olaparib) Reduced The Risk Of Disease Progression Or Death As First-Line Maintenance Treatment In Germline BRCA-Mutated Metastatic Pancreatic Cancer

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced positive results from the Phase 3 POLO trial.

Merck To Acquire Immune Design

Merck To Acquire Immune Design

Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Immune Design (NASDAQ:IMDZ), today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Immune Design for $5.

Merck Shares Drop After Keytruda Treatment Fails Late-Stage Liver Cancer Trial

Merck Shares Drop After Keytruda Treatment Fails Late-Stage Liver Cancer Trial

Merck shares slipped lower in pre-market trading Wednesday after the drugmaker said one of its key liver cancer treatments failed a late-stage trial only months after getting accelerated approval from the U.S. Food & Drug Administration.

Merck Provides Update On KEYNOTE-240, A Phase 3 Study Of KEYTRUDA® (pembrolizumab) In Previously Treated Patients With Advanced Hepatocellular Carcinoma

Merck Provides Update On KEYNOTE-240, A Phase 3 Study Of KEYTRUDA® (pembrolizumab) In Previously Treated Patients With Advanced Hepatocellular Carcinoma

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-240 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, plus best supportive care, for the treatment of patients with advanced...

FDA Approves Merck's KEYTRUDA® (pembrolizumab) For The Adjuvant Treatment Of Patients With Melanoma With Involvement Of Lymph Node(s) Following Complete Resection

FDA Approves Merck's KEYTRUDA® (pembrolizumab) For The Adjuvant Treatment Of Patients With Melanoma With Involvement Of Lymph Node(s) Following Complete Resection

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.

KEYTRUDA® (pembrolizumab) In Combination With Inlyta® (axitinib) Reduced Risk Of Death By Nearly Half Compared To Sunitinib As First-Line Treatment For Advanced Renal Cell Carcinoma (RCC)

KEYTRUDA® (pembrolizumab) In Combination With Inlyta® (axitinib) Reduced Risk Of Death By Nearly Half Compared To Sunitinib As First-Line Treatment For Advanced Renal Cell Carcinoma (RCC)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced presentation of the full results from the pivotal Phase 3 KEYNOTE-426 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with Inlyta (axitinib), a...

Merck Increases Focus On Advanced Prostate Cancer, Expanding Immuno-Oncology Program With Three New Phase 3 Trials

Merck Increases Focus On Advanced Prostate Cancer, Expanding Immuno-Oncology Program With Three New Phase 3 Trials

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of interim data from the Phase 1b/2 KEYNOTE-365 umbrella trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with various agents for...

AstraZeneca Surges as Oncology Sales Drive Q4 Earnings Beat, Solid 2019 Outlook

AstraZeneca Surges as Oncology Sales Drive Q4 Earnings Beat, Solid 2019 Outlook

AstraZeneca shares traded sharply higher Thursday after the U.K.-based drugmaker posted stronger-than-forecast fourth quarter earnings, and said 2019 revenues would continue to rise, thanks to increasing demand for its key cancer treatments.

Merck Becomes #5 Most Shorted Dow Stock, Replacing International Business Machines

Merck Becomes #5 Most Shorted Dow Stock, Replacing International Business Machines

The most recent short interest data has been released for the 01/31/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Merck Highlights Breadth Of Immuno-Oncology Research Program In Genitourinary Cancers At ASCO GU

Merck Highlights Breadth Of Immuno-Oncology Research Program In Genitourinary Cancers At ASCO GU

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new combination and monotherapy data from the company's broad immuno-oncology research program in genitourinary cancers - renal, prostate and bladder − will be...

Stocks Mixed Ahead of U.S.-China Trade Talks; Healthcare Sector Weighs on Dow

Stocks Mixed Ahead of U.S.-China Trade Talks; Healthcare Sector Weighs on Dow

The Dow Jones Industrial Average falls as investors eye progress in this week's renewed U.S.-China trade talks.

TheStreet Quant Rating: A+ (Buy)